Katherine Dawson - Concepedia

Author

Katherine Dawson

Biogen (United States)

Also Known As

Dawson, Katherine, K.T. Dawson, Katherine Dawson, Katherine T Dawson, Katherine T. Dawson, Kristy Dawson, Minhua Yang

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Biogen (United States)St. Josef-Hospital Ruhr University Bochum Medical University of Lodz Cleveland Clinic

About

Katherine Dawson is an author at Biogen (United States) specializing in medicine, neurology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	714
2	Education	1	1	33
3	Social Sciences	1	1	33
4	Civil Engineering	1	1	33
5	Culture	1	1	33

Katherine Dawson

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis Ralf Gold, Ludwig Kappos, Douglas L. Arnold, New England Journal of Medicine	2012	1.7K
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis Robert J. Fox, David H. Miller, J. Theodore Phillips, New England Journal of Medicine	2012	1.3K
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Ludwig Kappos, Ralf Gold, David H. Miller, The Lancet Relapsing-remitting Multiple SclerosisMedicineClinical NeurologyClinical TrialsNeurological Progress	2008	477
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS Robert J. Fox, Andrew Chan, Ralf Gold, Neurology Clinical Practice	2016	104
Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies Sreeja Gopal, Alvydas Mikulskis, Ralf Gold, Multiple Sclerosis Journal	2017	100
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study Michael Hutchinson, Robert J. Fox, David H. Miller, Journal of Neurology Neurological DisorderClinical NeurologyClinical TrialsNeurologyMultiple Sclerosis	2013	83
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study Douglas L. Arnold, Ralf Gold, Ludwig Kappos, Journal of Neurology	2014	73
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study Amit Bar‐Or, Ralf Gold, Ludwig Kappos, Journal of Neurology Neurological DisorderClinical NeurologyClinical TrialsNeurologyMultiple Sclerosis	2013	69
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study David H. Miller, Robert J. Fox, J. Theodore Phillips, Neurology	2015	65
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study Ludwig Kappos, Ralf Gold, Douglas L. Arnold, Multiple Sclerosis Journal	2013	64

Page 1